Trademark: 88331899
Status Code
Status Date
Tuesday, May 28, 2019
Serial Number
Mark Type
Filing Date
Friday, March 8, 2019
Published for Opposition
Tuesday, May 28, 2019

Trademark Owner History
Eli Lilly and Company - Owner At Publication

5 Pharmaceutical preparations namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, headaches, heart failure, hypoglycemia, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, Sjogren's syndrome, sleep disorders, spondyloarthropathy, ulcerative colitis; Diagnostic agents and substances for medical purposes; radiopharmaceutical diagnostic preparations for use in the diagnosis of neurodegenerative diseases and of oncology and of pain
The wording "RETZELEQ" has no meaning in a foreign language.

Trademark Events
May 28, 2019
Official Gazette Publication Confirmation E-Mailed
May 28, 2019
Published For Opposition
May 8, 2019
Notification Of Notice Of Publication E-Mailed
Apr 18, 2019
Approved For Pub - Principal Register
Apr 16, 2019
Assigned To Examiner
Mar 27, 2019
New Application Office Supplied Data Entered In Tram
Mar 12, 2019
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2019-07-15